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ABSTRACT
Objective The nature of the tumour-inﬁltrating
leucocytes (TILs) is known to impact clinical outcome in
carcinomas, including hepatocellular carcinoma (HCC).
However, the role of tumour-inﬁltrating B cells (TIBs)
remains controversial. Here, we investigate the impact of
TIBs and their interaction with T cells on HCC patient
prognosis.
Design Tissue samples were obtained from 112
patients with HCC from Singapore, Hong Kong and
Zurich and analysed using immunohistochemistry and
immunoﬂuorescence. RNA expression of CD19, CD8A,
IFNG was analysed using quantitative PCR. The
phenotype of freshly isolated TILs was analysed using
ﬂow cytometry. A mouse model depleted of mature B
cells was used for functional study.
Results Tumour-inﬁltrating T cells and B cells were
observed in close contact with each other and their
densities are correlated with superior survival in patients
with HCC. Furthermore, the density of TIBs was correlated
with an enhanced expression of granzyme B and IFN-γ,
as well as with reduced tumour viability deﬁned by low
expression of Ki-67, and an enhanced expression of
activated caspase-3 on tumour cells. CD27 and CD40
costimulatory molecules and TILs expressing activation
marker CD38 in the tumour were also correlated with
patient survival. Mice depleted of mature B cells and
transplanted with murine hepatoma cells showed reduced
tumour control and decreased local T cell activation,
further indicating the important role of B cells.
Conclusions The close proximity of tumour-inﬁltrating
T cells and B cells indicates a functional interaction
between them that is linked to an enhanced local
immune activation and contributes to better prognosis
for patients with HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the sixth most
common cancer, but the second leading cause of
death by cancer worldwide.1 The link between
inﬂammation due to hepatitis virus infection or
alcoholism and HCC tumorigenesis is well known,2
but the role of the immune response in cancer pro-
gression or prognosis requires further elucidation.
Signiﬁcance of this study
What is already known on this subject?
▸ We have previously shown that the nature of
tumour-inﬁltrating leucocytes has an impact
on hepatocellular carcinoma (HCC) patient
survival.
▸ Multiple costimulatory molecules involved in T
cell–B cell interaction have been implicated in
cancer prognosis.
▸ The role of tumour-inﬁltrating B cells (TIBs),
however, remains controversial with several
studies reporting contradictory ﬁndings.
What are the new ﬁndings?
▸ We show that the density of TIBs correlates
with an enhanced expression of granzyme B
and IFN-γ as well as with reduced viability of
tumour cells.
▸ We demonstrate the densities of T cells and B
cells that are in close proximity to each other,
costimulatory molecules CD27 and CD40 and
activation marker CD38, all indicative of local
immune activation were associated with better
survival in a total of 112 patients from
Singapore, Hong Kong and Zurich, that is,
irrespective of patient ethnicity and disease
aetiology.
▸ We use a murine model depleted of mature B
cells and transplanted with murine hepatoma
cell lines to demonstrate the critical role of B
cell in tumour control and local T cell
activation.
How might it impact on clinical practice in
the foreseeable future?
▸ Improved understanding of the importance of
T cell–B cell interaction, the costimulatory
molecules involved and the resulting activation
of local immune response in HCC progression.
▸ Providing evidence supporting clinical
development of agonists targeting
costimulatory molecules for cancer
immunotherapy.
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Tumour-inﬁltrating T cells, especially CD8+ T cells, have been
shown to play a critical role in controlling tumour progression.3
Studies in many human cancers, including HCC, demonstrated
a positive correlation between the density of T cells and better
patient prognosis.4 On the other hand, the involvement of B
cells in cancer development and progression is rather controver-
sial. Previous ﬁndings from a diethylnitrosamine-induced liver
cancer mouse model showed that T cells and B cells are import-
ant in suppressing tumour development and progression.5
Several B cell activation genes were reported to be downregu-
lated in patients with HCC with poor prognosis suggesting their
protective roles in tumour progression.5 Others, however, found
that a special subset of B cells deﬁned as regulatory B cells
(Bregs) with CD19+CD24hiCD38hi phenotype was enriched in
the tumour microenvironment and was associated with progres-
sion of various cancers, including HCC.6 7
The interaction between T cells and B cells is known to be
critical in the activation of local immune response in several
inﬂammatory conditions, including cancer.8 Multiple costimula-
tory and coinhibitory molecules that are expressed on T cells
have been the recent targets of a new generation of immuno-
therapies, such as anti-CTLA-4, anti-PD-1/PD-L1 or anti-OX40
antibodies, which aim to enhance the local antitumour immune
response either through blocking coinhibitory checkpoint recep-
tors or activating costimulatory receptors expressed on tumour-
inﬁltrating T cells.9 The balance of these molecules/receptors
has been shown to be paramount in eliciting efﬁcient antitu-
mour immune response, supporting the basis of combinatorial
strategy in immunotherapy.10
We here present an extensive retrospective study on the role
of T cells and B cells from a total of 112 patients with HCC
from Singapore, Hong Kong and Zurich, that is, with different
ethnicities as well as disease aetiologies. By investigating the
archived tissues from patients with HCC, we found that the
densities of both T cells and B cells are associated with better
patient survival and decreased tumour aggressiveness. The
phenotype of both tumour-inﬁltrating T and B cells suggests that
they acquire an activated phenotype as a result of their close
proximity and interaction. A mouse model depleted of mature B
cells further demonstrated the key role of B cells in controlling
tumour progression and local T cell activation.
MATERIALS AND METHODS
Patients
One hundred and twelve formalin-ﬁxed parafﬁn-embedded
(FFPE) patient tissue samples from resected HCC were obtained
from the National Cancer Centre (NCC), Singapore (n=40); the
Queen Mary Hospital, Hong Kong (n=45) and the University
Hospital Zurich, Switzerland (n=27). The tissues were used for
immunohistochemistry (IHC) or immunoﬂuorescence (IF) label-
ling. Among these, 81 RNA samples were also obtained for gene
expression analysis. All samples were obtained with ethics com-
mittee approval from patients who underwent curative resection
from 1991 to 2009. A table comparing patient characteristics
from different cohorts is listed in online supplementary table S1.
Immune cells were freshly isolated from HCC tumour, adjacent
non-tumour tissues as well as peripheral blood mononuclear
cells (PBMCs) from seven patients with HCC and were analysed
using ﬂow cytometry. Patient consent was obtained from each
case with institutional review board (IRB) approval.
Immunohistochemistry and immunoﬂuorescence
IHC and IF staining were performed on FFPE tissue samples as
described previously.11 The antibodies used are listed in online
supplementary table S2. IF images were captured using
Olympus FluoView FV1000 confocal microscope with 40,6-dia-
midino-2-phenylindole (DAPI) as the nuclear marker. IHC
images were obtained with an Olympus DP20 camera attached
to a CX31 microscope. Multiplex tissue ﬂuorescence staining
was performed with Opal staining system and images were
acquired using Mantra platform (Perkin Elmer).12–14
Quantiﬁcation of positively stained cells was performed using
ImagePro Software and veriﬁed with manual counting from 5 to
10 random ﬁelds at 100×magniﬁcation. The mean number
from all ﬁelds from each patient sample was taken and the
density of cell of interest (number/mm2) was calculated based
on the area of each tumour ﬁeld at 100×magniﬁcation mea-
sured as 1.27 mm2. The deﬁnitions of peritumour, intratumoral
and non-tumour at the tumour margin are illustrated in online
supplementary ﬁgure S1.
Gene expression analysis
Quantitative PCR (qPCR) assay was performed on a total of 81
mRNA samples as described previously.11 Brieﬂy, primers were
designed using Primer3 and qPCR assay was performed using
iTaq SYBR Green Supermix with ROX (Bio-Rad Laboratories).
Relative RNA expression of CD19, CD8A and IFNG was calcu-
lated by normalisation to the housekeeping gene beta-actin
(ACTB) using MxPro Software (Stratagene). The primers used
were as follows: CD19 primers: FW0 TCCTTCT
CCAACGCTGAGTC, RV0 GCTCAGGAAGTCCATTGTCC;
CD8A primers: FW0 CCCTTTACTGCAACCACAGG, RV0
GTCTCCCGATTTGACCACAG; IFNG primers: FW0
ATGCAGGTCATTCAGATGTAGC, RV0 TGTCACTCTCCTCT
TTCCAATTC and ACTB primers: FW0 CCAACCGCGA
GAAGATGA, RV0 TAGCACAGCCTGGATAGCAA.
Flow cytometry
PBMCs were isolated using standard ﬁcoll procedure and
tumour dissociation was performed as previously described.15
The immune cells were stained with antibodies as listed in
online supplementary table S2.
Mice
Male wild-type (WT) C57BL/6 mice at 6–7 weeks of age were
used. To induce in vivo B cell depletion, one single dose of
mouse anti-mouse CD20 (clone 5D2, isotype IgG2a, Genentech)
or isotype-matched control mAb (100 μg) was injected in 200 μL
phosphate buffered saline (PBS) through lateral tail veins.16 A
single dose of this depleting antibody ensures the B cell depletion
from Day 7 to as long as 57 days post-injection.16 Sixteen days
after, 3×106 Hepa1–6 hepatoma cell lines were transplanted into
both ﬂanks of the mice. Tumour growth was monitored using cal-
liper on Days 17, 19, 23, 26 and 30 before the mice were sacri-
ﬁced on Day 31. Tumours and spleens were harvested for
analysis of tumour-inﬁltrating leucocytes (TILs) using ﬂow cyto-
metry. Antibodies used include CD45, CD3 CD8, CD19, gran-
zyme B (GZB), PD-1 (eBiosciences), CD4, NK1.1, CD69 and
IFN-γ (BioLegend). Animal care and all experimental procedures
were approved by the Institutional Animal Care and Use
Committee from Biological Resource Centre, A*STAR,
Singapore.
Statistical analysis
Kaplan–Meier univariate survival analysis was performed using
classiﬁcation as ‘low’ or ‘high’ according to the median densities
of cells of interest and p values are reported using log-rank
(Mantel–Cox) test with HR and 95%CI. For correlation
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analyses, p values and correlation coefﬁcients (r) were calculated
using the Pearson’s correlation test. Both tests were performed
using GraphPad Prism V.6.03 (GraphPad Software).
Multivariate analysis by Cox proportional hazards model was
used to examine the predictive value of densities of tumour-
inﬁltrating CD3+ T cells and CD20+ B cells in the context of
other clinical variables. The variables were chosen with a step-
wise approach to calculate Akaike’s information criteria (AIC),
starting from a full model comprising CD3, CD20, grade, stage,
age and pairwise interactions. At each iteration step, variables
were removed or added to the current model and AIC were
calculated for the new models until the model being tested
showed a lower AIC. The ﬁnal model we reached is as follows:
coxph (formula=Surv(survival, death)∼CD3+CD20+grade+as.
factor(stage)+age+CD3:CD20+CD3:grade+CD20:age+grade:
age+as.factor(stage):age). Stage is considered as a factor where
stage I is used as the baseline.
RESULTS
The density of tumour-inﬁltrating B cells correlates with
that of the tumour-inﬁltrating T cells
Given the controversial role of B cells in tumour progression,
especially in HCC, we investigated whether tumour-inﬁltrating
B cells (TIBs) could play a role in HCC progression. First, we
performed IF staining for CD20+ B cells together with CD3+ T
cells in tumour tissue samples from patients with HCC. We
observed that CD20+ B cells are in close proximity to CD3+ T
cells forming either a small cluster (ﬁgure 1A) or, less frequently
(one-third of the cases), a tertiary lymphoid-like structure with
T cells and B cells organised in a feature resembling a germinal
Figure 1 Tumour-inﬁltrating T and B cells are in close contact and their densities are correlated with each other within the hepatocellular
carcinoma (HCC) microenvironment. Representative immunoﬂuorescence images on CD20 (red), CD3 (green) and nuclear staining with DAPI (blue)
showing (A) a small aggregate and (B) a tertiary lymphoid structure formed with T and B cells in HCC. 400× magniﬁcation. Bar=30 μm. (C)
Representative images from multiplex tissue ﬂuorescence staining using Opal (Perkin Elmer) showing DAPI (blue), CD20 (magenta), CD8 (green) and
CD68 (yellow). 200× magniﬁcation. Bar=50 μm. (D) The density of tumour-inﬁltrating B cells (number of cells/mm2) is correlated with
tumour-inﬁltrating CD3+ (n=103) and CD8+ (n=70) T cells. (E) Relative RNA expression of CD19 (B cell marker) and CD8A (CD8+ T cell marker)
normalised to the housekeeping gene ACTB is correlated with each other (n=81). Graphs show p value against Pearson correlation coefﬁcients r.
****p<0.0001.
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centre (ﬁgure 1B). In almost all cases, T cells and B cells are in
close proximity or even in contact with one another. Notably,
such structures appear within the tumour bed, as well as at the
inﬁltrating margin of tumours. About 70% of the bigger clusters
resembling tertiary lymphoid structures appear at the inﬁltrating
margin of tumours, which are also considered as the intratu-
moral regions. A typical example showing strong B cell inﬁltra-
tion at the invasive margin and in the tumour bed is given in
online supplementary ﬁgure S1. Importantly, such interaction is
speciﬁc to T cells where multiplex tissue staining with Opal
(Perkin Elmer) showed that CD20+ B cells form a cluster with
CD8+ T cells while not with the CD68+ macrophages which
are abundant in HCC tissues (ﬁgure 1C). Further IHC staining
and quantiﬁcation for CD20 and CD3 on tumour tissues from a
total of 112 patients with HCC from Singapore, Hong Kong
and Zurich demonstrated that, indeed, the density of CD20+ B
cells closely correlates with the densities of both CD3+ and
CD8+ T cells (see ﬁgure 1D and online supplementary
ﬁgure S2A). A weak correlation was also observed between the
densities of CD20+ B cells and CD56+ NK cells, but not with
CD68+ macrophages (see online supplementary ﬁgure S2B). To
further conﬁrm these IHC data, we performed qPCR on RNA
samples from a total of 81 patients with HCC and observed a
striking correlation between CD19 (another marker for B cells)
and CD8A gene expression in these tumour samples (ﬁgure 1E).
Taken together, IHC and transcriptome analysis conﬁrm that
the density of TIBs correlates with T cell inﬁltration to HCC.
The density of TIBs correlates with T cell and NK cell
activation and decreased tumour cell viability
We further investigated whether the intratumoral density of TIBs
is associated with any particular phenotypes of TILs or tumour
cells in microenvironment of HCC. First, we found that the
density of TIBs correlates with the intratumoral density of GZB,
an activation marker for both T cells and NK cells by IHC stain-
ing (ﬁgure 2A). Additionally, qPCR was performed on RNA
samples from 75 patients with HCC and the correlation between
CD19 and IFNG (another activation marker for T and NK cells)
expression was also observed (ﬁgure 2B). Further double IHC
staining on tissues and ﬂow cytometry analysis on freshly isolated
TILs demonstrated that T and NK cells are the major sources of
GZB and IFN-γ (see online supplementary ﬁgure S3A, B).
Figure 2 The density of
tumour-inﬁltrating B cells (TIBs) is
correlated with an enhanced T and NK
cell activation and reduced tumour cell
viability. (A) The density of CD20+ TIBs
is correlated with the density of total
granzyme B (GZB)+ tumour-inﬁltrating
leucocytes (n=50). (B) RNA expression
of CD19 correlates with IFNG,
activation marker for T and NK cells
(n=75). (C) Graphs showing correlation
of densities of CD20+ TIBs with
CD56+GZB+ cells (left) and CD8+GZB+
cells (right). (D) The density of CD20+
TIBs negatively correlated with
Caspase-3+ tumour cells (n=54) and
positively with Ki-67+ tumour cells
(n=40). Graphs show p value against
Pearson correlation coefﬁcients r.
*p<0.05; **p<0.01; ****p<0.0001.
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Indeed, the density of TIBs correlated with the densities of
CD8+ Tcells and CD56+ NK cells that express GZB (ﬁgure 2C).
Meanwhile, we also detected GZB expression by CD68+ macro-
phages in multiplex tissue ﬂuorescence staining by Opal system
(see online supplementary ﬁgure 3C). As both GZB and IFN-γ
represent activation markers for cytotoxic T and NK cells, the
density of TIBs is correlated with the activation of both CD8+ T
and CD56+ NK cells intratumorally and hence possibly leads to
an enhanced local antitumour immune response. To demonstrate
that TIBs are indeed correlated with an enhanced antitumour
immune response, we analysed the density of TIBs in the context
of the tumour viability markers. We observed that the density of
TIBs correlates with the density of apoptotic tumour cells mea-
sured as activated caspase-3-positive tumour cells (see ﬁgure 2D
and online supplementary ﬁgure S4). Conversely, the density of
TIBs negatively correlates with the density of proliferating
tumour cells as identiﬁed by their expression of Ki-67 (ﬁgure 2D
and online supplementary ﬁgure S4).
The densities of tumour-inﬁltrating T cells and B cells are
associated with superior HCC patient survival
We previously demonstrated that the densities of tumour-
inﬁltrating CD8+ Tcells and CD56+ NK cells are associated with
Figure 3 Densities of tumour-inﬁltrating T and B cells are associated
with superior hepatocellular carcinoma (HCC) patient survival. (A)
Representative immunohistochemistry images showing higher densities
of CD20+ B and CD3+ T cells (in blue) from long versus short survival
patient. Survival proﬁle is based on either ≥(long) or <(short) median
survival of 4.5 years. Bar=50 μm. (B) Kaplan–Meier (KM) analysis graph
showing densities of CD20+ B (n=112) and CD3+ T (n=103) cells are
associated with favourable HCC patient survival. (C) KM analysis graph
showing the patient survival proﬁle by combining the densities of both
CD20+ B and CD3+ T cells. CD3hiCD20hi (n=39), CD3hiCD20lo (n=12),
CD3loCD20hi (n=13) and CD3loCD20lo (n=38). (D) KM analysis showing
survival proﬁles of patients with CD3hiCD20hi (n=39) versus
CD3loCD20lo (n=38). lo and hi indicate ≥(low) or <(high) median
densities of CD20+ B cells (16 cells/ mm2 of tumour area) and CD3+
T cells (95/mm2 of tumour area). Graphs show p=log-rank test p value.
***p<0.001; ****p<0.0001.
Table 2 Multivariate survival analysis by Cox regression model
Variables HR (95% CI) p Value
CD3+ T cell density 1.0086 (1.0010 to 1.0160) 0.0213*
CD20+ B cell density 1.0799 (1.0030 to 1.1630) 0.0424*
Grade 924 (54.42 to 15 700) 2.30e−06***
as.factor (stage) II 25.3168 (0.1016 to 6308) 0.2511ns
as.factor (stage) III 0.1002 (7.192e−04 to 13.97) 0.3611ns
as.factor (stage) IV 1411 (3.160 to 6.302e+05) 0.0198*
Age 1.2322 (1.092 to 1.390) 6.80e−04***
CD3:CD20 0.9999 (0.9999 to 1.000) 0.1795ns
CD3:grade 0.9946 (0.9912 to 0.9981) 0.0022**
CD20:age 0.9987 (0.9975 to 0.9998) 0.0256*
Grade:age 0.9238 (0.8837 to 0.9658) 0.0005***
as.factor (stage) II:age 0.9810 (0.8997 to 1.0700) 0.6643ns
as.factor (stage) III:age 1.0790 (0.9977 to 1.1670) 0.0571ns
as.factor (stage) IV:age 0.9498 (0.8636 to 1.0450) 0.2892ns
*p<0.05 **p<0.01 ***p<0.001 ****p<0.0001.
Table 1 Univariate analysis of various clinical parameters and densities of intratumoral CD20+ B cells and CD3+ T cells as predictors of patient
survival
Variables Number (%) Median (range) HR (95% CI) p Value
Grade (1+2/3+4) 82/21 (80/20) NA 0.4 (0.1 to 0.7) 0.0055**
TNM stage (I+II/III+IV) 64/45 (59/41) NA 0.4 (0.2 to 0.7) 0.0020**
Tumour size, cm (<median/≥median) NA 5 (0.7–27) 0.6 (0.3 to 1.0) 0.0702ns
AFP (ng/mL) (<median/≥median) NA 52 (1–>70 700) 0.8 (0.5 to 1.4) 0.4092ns
Age (<median/≥median) NA 58 (20–84) 0.5 (0.3 to 0.8) 0.0106*
Viral status (non-infected/HepB+C) 37/72 (34/66) NA 1.1 (0.6 to 2.0) 0.8163ns
Race (others/Chinese) 26/83 (24/76) NA 1.3 (0.6 to 2.6) 0.4985ns
Gender (female/male) 21/89 (19/81) NA 0.7 (0.3 to 1.4) 0.2903ns
CD20+ B cell density (<median/≥median) NA 16 (0.3–199) 3.1 (1.9 to 6.0) <0.0001****
CD3+ T cell density (<median/≥median) NA 95 (5–840) 2.9 (1.7 to 5.5) <0.0001****
*p<0.05 **p<0.01 ***p<0.001 ****p<0.0001.
AFP, alpha-fetoprotein; TNM, tumour, node, metastases.
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longer HCC patient survival.11 Given the above observation, we
investigated the association between the densities of intratumoral
CD20+ B cells and CD3+ Tcells and HCC patient survival. IHC
staining and quantiﬁcation for CD20 and CD3 were performed
as described above. The densities of both intratumoral CD20+ B
cells and CD3+ T cells were associated with superior HCC
patient survival (ﬁgure 3A, B and table 1). Since CD20+ B cells
are located in close proximity to T cells, we then investigated
their inﬂuence on patient survival when their densities are taken
into consideration together (ﬁgure 3C). We observed that
patients with high intratumoral densities of both CD20+ B cells
and CD3+ T cells had longer survival compared with those with
low densities of both subsets (ﬁgure 3D vs ﬁgure 3B; HR=4.8 vs
3.1 and 2.9 for either CD20+ B cells or CD3+ T cells, respect-
ively). The densities of intratumoral CD3+ T cells and CD20+ B
cells (TIBs) were both independent predictors of HCC patient
survival as shown in the multivariate Cox regression analysis
together with grade, stage and age (table 2). The interaction
between CD3 and grade was signiﬁcantly associated with sur-
vival, suggesting that the relationship between CD3 and survival
varied between different grades. The interaction between CD20
and age is also signiﬁcant, which suggests the relationship
between CD20 and survival varied at different age (table 2). For
instance, the effect of CD3 on survival is more profound in the
group of patients with advanced grades (3 or 4 vs 1 or 2), while
the effect of CD20 on survival is more profound in the group of
patients with advanced age of more than 58 years old.
Costimulatory molecules CD27 and CD40 expressed on both
T cells and B cells correlate with patient survival
Based on the above observations, T and B cell proximity poten-
tially reﬂects functional interaction. The interaction between
Figure 4 CD27 and CD40 costimulatory molecules are associated with superior hepatocellular carcinoma (HCC) patient survival. (A) Kaplan–Meier
(KM) analysis graph showing the density of CD27+ tumour-inﬁltrating leucocytes (TILs) is associated with superior HCC patient survival. n=80.
(B) Representative immunohistochemistry images showing CD27 (red) with CD3 (blue) and CD20 (blue) at 200× magniﬁcation. Bar=30 μm.
(C) Representative immunoﬂuorescence (IF) images at 800× magniﬁcation showing DAPI (blue), CD20 (red), CD3 (green), CD27 (white) and merged
image on the far right. Bar=20 μm. (D) KM analysis graphs showing that densities of CD27+CD3+ (left, n=28) and CD27+CD20+ (right, n=39) are
associated with superior patient survival. (E) KM analysis graph showing that the density of CD40+ TILs is associated with superior HCC patient
survival (n=54). (F) Representative IF images at 800× magniﬁcation showing DAPI (blue), S100 (red), CD20 (green), CD40 (white) and merged
image on the far right. Bar=20 μm. Graphs show p=log-rank test p value. *p<0.05; **p<0.01.
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T cells and B cells could result in bidirectional T cell and B cell
activation. Costimulatory molecules indicative of B cell activa-
tion such as CD27 could be an important indicator for such
interaction/activation state.17 Indeed, the expression of CD27
on TILs within HCC determined by IHC analysis is positively
associated with overall patient survival (ﬁgure 4A). Closer exam-
ination of CD27+ cells showed that both T cells and B cells can
express CD27 in HCC (ﬁgure 4B, C). On average, 48% of total
CD20+ B cells (range, 1–90%) and 64% of total CD3+ T cells
(range, 4–98%) express CD27. It was previously shown that
CD27 is expressed on most T cells, including naive T cells, but it
is only upregulated on activated B cells.18 This indicates that
close to half of the TIBs are activated (CD27+). The majority of
CD27+ population consists of CD3+ T cells (average of 59%;
range, 13–88%), while CD20+ B cells make up 12% (range,
2–42%) of the total CD27+ population. Importantly, the fre-
quency of either CD3+ T cells or CD20+ B cells that express
CD27 is positively associated with superior patient survival
(ﬁgure 4D).
The above results suggest that the interaction between B
and T cells is an important event leading to their activation
and hence tumour control. To test this, we probed for
another important costimulatory molecule, CD40, which is
necessary for productive interactions between T and B cells.8
The ligation between CD40 on antigen-presenting cells such
as B cells and dendritic cells and CD40 ligand expressed on T
cells is known to trigger T cell activation.19 The density of
CD40+ TILs was indeed associated with better HCC patient
survival (ﬁgure 4E). We observed that CD40 is expressed on
average in 54% (range, 11–99%) of the total CD20+ B cells
within the HCC microenvironment. On the other hand, 54%
(range, 22–81%) of CD40+ cells are CD20− B cells, with
other CD40-expressing cells including S100+ dendritic cells
(ﬁgure 4F).
Expression of CD38 on TILs correlates with longer patient
survival
Next, we probed for the expression of CD38 on TILs in HCC.
CD38 is expressed on activated B cells such as germinal centre
B cells, memory B cells, plasmablasts or plasma cells.20 It is
also expressed on other immune cells such as T and NK cells
upon activation21 22 or monocytes.23 Interestingly,
CD27+CD38+CD138+ plasma cells were observed within
HCC tumours and in most cases near the margin of the
tumours (ﬁgure 5A). The CD38+CD138+ plasma cells are a
rare population within the tumour with only about 9 cells/mm2
compared with 40 cells/mm2 of CD20+ B cells. Most of the
CD38+ cells are, however, CD20− (on average, only 0.8%
(range, 0–5%) of the entire CD38+ population is
CD38+CD20+) and CD27+ (on average, 58% (range, 30–99%)
of total CD38+ cells coexpress CD27). This indicates that half
of the CD38+ TILs could potentially be activated T cells, NK
cells, monocytes or plasma cells which lack CD20 expression.
Indeed, ﬂow cytometry analysis on freshly isolated TILs from
tumour samples taken from patients with HCC showed that
majority of the CD38+ TILs are either CD3+ T cells (average
37%) or CD14+ monocytes (average 29%) (ﬁgure 5B). Plasma
cells detectable as CD38+CD138+CD27+CD19− (average 5%
Figure 5 CD38+ tumour-inﬁltrating leucocytes (TILs) are associated with superior hepatocellular carcinoma (HCC) patient survival.
(A) Representative immunoﬂuorescence images at 800× magniﬁcation showing DAPI (blue), CD138 (red), CD27 (green), CD38 (white) and merged
image on the far right. Bar=20 μm. (B) Population of CD38+ TILs isolated from freshly resected HCC specimens (n=7), each dot represents one
tumour. Deﬁnitions: T cells (CD3+), B cells (CD19+CD24−), regulatory B cells (Bregs) (CD24+CD19+), plasma cells (CD138+), NK (CD56+), NKT
(CD3+CD56+) and monocytes (CD14+). Graph shows mean and SD. Right, pie chart showing representative distribution of CD38+ TILs based on the
average percentage from seven HCC tumours. (C) Kaplan–Meier analysis graph showing that CD38+ TILs are associated with superior HCC patient
survival (n=59). Graphs show p=log-rank test p value. ***p<0.001. NKT, natural killer T cells.
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of total CD38+ TILs) and Bregs as deﬁned by
CD38+CD24+CD19+ (average 4% of total CD38+ TILs) are
both rare events in TILs (ﬁgure 5B). As plasma cells produce
large quantities of antibodies, we also probed for human IgG
expression in HCC tissues. Indeed, antibodies were shown to be
bound to HCC tumour cells and costained with plasma cell
marker CD138 (see online supplementary ﬁgure S5A, B).
Importantly, the density of CD38+ TILs is associated with
better HCC patient survival (ﬁgure 5C). Again, this indicates
the activated immune microenvironment of HCC plays a critical
role in superior HCC patient survival.
Depletion of CD20+ mature B cells resulted in reduced
tumour control and decreased local T cell activation
Next, to further strengthen our claim on the important role of
TIBs in HCC, we depleted the mature B cells from WT C57BL/
6 mice using anti-mouse CD20 mAb or with isotype-matched
mAb (Genentech) as control according to previous report.16
These mice were then transplanted with murine hepatoma cell
lines Hepa1–6 on Day 16 after B cell depletion and tumour
growth was monitored for another 15 days until Day 31. First of
all, we established that B cells were successfully depleted from
these mice even on Day 31 (ﬁgure 6A). Tumour growth was
Figure 6 CD20+ B cell depletion
reduced tumour control and decreased
T cell activation. Wild-type (WT)
C57BL/6 mice were transplanted with
Hepa1–6 cells and tumour growth was
monitored. (A) Successful B cell
depletion showing less than 0.3% of B
cells present in the spleens of the mice
at Day 31 after injection with
anti-mouse CD20 mAb compared with
more than 30% of B cells in those
injected with isotype control mouse
IgG2a antibody. (B) Tumour growth
was enhanced in B cell-depleted mice
compared with control mice. n=4–8
tumours in each group. (C) Left,
representative images showing larger
tumours harvested from B cell-depleted
mice versus control mice on Day 31.
Right, graph showing bigger tumours
by weight (g) harvested from B
cell-depleted mice versus control mice.
Percentage (%) of (D) IFN-γ and
granzyme B (GZB). (E) CD69 and (F)
PD-1 on CD4+ T, CD8+ T and NK1.1+
NK cells isolated from tumours harvest
from B cell-depleted mice versus
control mice. All graphs show *p<0.05
from unpaired Student’s t test except
(B) p<0.0001 from one-way ANOVA
test.
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signiﬁcantly enhanced in mice depleted of B cells (ﬁgure 6B)
resulting in larger tumour size at harvest on Day 31 (ﬁgure 6C).
We observed no signiﬁcant difference in tumour-inﬁltrating
CD3+ T cells, but a corresponding reduction of CD20+ B cells
in tumours from control undepleted mice versus CD20-depleted
mice (data not shown). To support our above hypothesis that
TIBs play an important role in local T cell activation, we then
examined the T cell activation status from TILs. Indeed, CD4+
T cell activation was reduced with B cell depletion shown by the
reduced expression of IFN-γ, GZB (ﬁgure 6D) and CD69, an
early activation marker (ﬁgure 6E). Notably, we do not observe
a signiﬁcant difference in CD8+ T cell activation in this current
model. However, the expression of PD-1, an inhibitory receptor
marker, was enhanced on CD8+ TILs upon B cell depletion
(ﬁgure 6F). This indicates that the activation of CD8+ T cells
was also inﬂuenced by CD20+ B cells. In conclusion, we demon-
strated TIBs play an important role in tumour control via T cell
activation.
DISCUSSION
We demonstrated that densities of both T and B cells are asso-
ciated with HCC patient survival, and that they are in close
proximity and seemingly at cell-to-cell contact with one
another, most likely an indication of a functional interaction
between them. To support this hypothesis, we found that the
density of TIBs correlates with the number and activation status
of both T and NK cells and coincides with reduced tumour cell
viability. Using a mouse model transplanted with murine hepa-
toma cells, we demonstrated that the depletion of B cells
resulted in an enhanced tumour growth and reduced local T cell
activation. We conclude that the interaction between B and T
cells is an important event leading to their activation and hence
contributing to better tumour control in HCC.
Our current study partially contradicts an earlier report
showing that circulating Bregs deﬁned as CD19+CD24hiCD38hi
population promoted HCC progression via the CD40/CD40L
signalling pathway.6 Instead, we found that Breg cells represent
a minor population in TILs counting for less than 5% of the
CD38+ TILs in fresh tumour samples. It may also be difﬁcult to
directly compare our study, based on TIBs, with Shao’s report
on circulating Bregs. Rather, our ﬁndings support and extend
several other studies consistent with antitumour activity of intra-
tumoral B cells.5 24 25 For instance, Schneider et al5 reported
that adaptive immunity, in particular T and B cells, is critical for
the suppression of HCC progression. On the other hand,
Nielson et al described CD20+ TIBs with an atypical CD27−
memory phenotype to be correlated with better prognosis in
ovarian cancer.25 Both studies highlighted the importance of T
and B cell interaction in triggering functional adaptive immune
response.
The role of costimulatory molecules CD27/CD70 in tumour
control has been widely reported.26–28 Previous studies showed
that CD27 is expressed on most T cells, including naive T cells,
and its expression is increased upon Tcell activation, but downre-
gulated as T cells differentiate towards effector phenotypes.29
However, it has also been shown that in secondary lymphoid
organs, CD27 expression is retained on central memory Tcells.30
Its expression on B cells, on the other hand, is usually detected
on activated18 and memory B cells.31 32 CD27 was reported to
play an important role in T cell expansion and survival as well as
in B cell activation and antibodies production.26 The expression
of CD27 on intratumoral B cells could therefore be indicative of
their activation and active local immune response within the
tumour microenvironment. It was previously shown that the
population of CD19+CD27+ B cells was decreased in HCC.33
This could indicate a negative feedback mechanism during
tumour progression. In the current study, we demonstrated that
both CD27+ Tcells and CD27+ B cells are present in the tumour
of patients with HCC and that their densities are associated with
longer patient survival. Furthermore, we demonstrated the pres-
ence of CD27+CD38+CD138+ plasma cells in the tumour
microenvironment. CD38+ TILs, which could be activated Tand
NK cells,21 22 germinal centre B cells, memory B cells, plasma-
blasts, plasma cells34 or monocytes,23 were also shown to be asso-
ciated with better patient survival.
This study also showed a correlation of CD40+ cells with
better HCC patient survival. CD40 is an important costimula-
tory molecule expressed on B cells that upon ligation with
CD40 ligand leads to activation of both T and B cells.35 CD40
agonists have been tested as cancer immunotherapies in recent
years.36 It was previously reported that CD40 ligand-activated B
cells transfected with tumour total RNA isolated from HCC
cells were able to induce cytotoxic T cell response ex vivo.26
The current study is the most comprehensive study of costimula-
tory molecules in HCC, since it involves analysis of the largest
number of HCC cases and largest number of costimulatory
molecules indicative of T and B cell interaction thus far.
In the mouse model transplanted with Hepa1–6 cells, we
clearly demonstrated the role of TIBs in tumour control
whereby their depletion leads to an enhanced tumour growth
and reduced local T cell activation. The effect on T cell activa-
tion was mainly observed on CD4+ T cells where the expression
of IFN-γ, GZB and CD69 was signiﬁcantly decreased. On
CD8+ T cells, however, PD-1 was signiﬁcantly increased when B
cells were depleted in these mice. In this particular case, we
refer to PD-1 marker as inhibitory receptor rather than an
exhaustion marker since the expression of IFN-γ and GZB from
CD8+ T cells was not signiﬁcantly reduced in B cell-depleted
animals.37 This is somehow in contrast to our observation in
human HCCs showing that B and T cell interaction leads to
CD8+ T cell activation marked by the expression of IFN-γ and
GZB. We believe that this difference is due to the chronic effect
of B cells, which interact ﬁrst with CD4+ T cells leading to the
enhanced local immune response and eventually to the activa-
tion of CD8+ T cells.38–40 This explanation is consistent with
the fact that animal studies were performed within 15 days after
tumour transplantation, while the human HCC samples were
examined years after the tumours were established.
In conclusion, this study provides comprehensive data from
patients with HCC, indicating a critical role of T and B cell
interaction in cancer progression. Our ﬁndings warrant further
investigations for the design of future immunotherapies leading
to local immune response and improved patient survival.
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